市场调查报告书
商品编码
1472989
全球药用辅料市场:依类型、功能、最终用户、地区、机会、预测,2017-2031 年Pharmaceutical Excipients Market Assessment, By Type, By Functionality, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
2024-2031年预测期间,全球药用辅料市场规模将以7%的复合年增长率扩大,从2023年的111.1亿美元增长到2031年的190.8亿美元。 近年来,市场经历了显着成长,预计未来将保持强劲的扩张速度。
多种因素正在推动全球药用辅料市场的成长,包括全球人口中慢性病盛行率的增加和老年人口的增加。 对仿製药的需求不断增长以及公共和私人公司投资和研发活动的增加正在促使该市场的成长。 此外,有利的监管制度、多家顶级公司的存在、合资活动、新进入者以及频繁的新产品发布正在加速全球药用辅料市场的成长。
全球药用辅料市场正在经历强劲成长,这主要是由于世界人口中慢性病和传染病发病率的增加。 随着人口老化,免疫系统减弱,感染慢性病和传染病的可能性增加,进一步加速了对治疗这些疾病的赋形剂等药品的需求。 製药业的成长以及为满足不断增长的药品需求而对仿製药的需求不断增加,促使製药公司对使用药用辅料进行药物发现的投资兴趣增加。 市场进入者增加研发活动以开发新型高效药用辅料、有利的监管框架以及市场进入者频繁推出产品对于加强全球药用辅料市场至关重要。 此外,併购、合作伙伴关係和分销协议等组织之间持续的合作活动正在进一步推动全球药用辅料市场的发展。 例如,2023年11月,IFF和BASF製药解决方案部门宣布合作,将IFF领先的药用辅料品牌引入BASF的虚拟製药助理平台ZoomLab。 该平台使研究人员能够预测和分析开发新药物配方和克服配方课题所需的正确辅料。
本报告检视了全球药用辅料市场,并提供了市场概况,包括依类型、功能性别、最终用户、地区和进入市场的公司概况划分的趋势。
Global pharmaceutical excipients market is projected to witness a CAGR of 7% during the forecast period 2024-2031F, growing from USD 11.11 billion in 2023 to USD 19.08 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Various factors, such as the increasing prevalence of chronic diseases among the global population and a rising geriatric population drive growth in the global pharmaceutical excipients market. Growing demand for generic drugs, along with increased investment and research and development activities by public and private firms, leads to the growth of this market. Moreover, a favorable regulatory system, the presence of several top players and collaborative venture activities, new entrants, and frequent new product launches accelerate the growth of the global pharmaceutical excipients market.
The global pharmaceutical excipients market is undergoing robust growth, primarily due to the increased prevalence of chronic and infectious diseases among the global population. The rising aging population increases the probability of being affected by chronic or infectious conditions due to lack of immunity, further accelerating demand for pharmaceutical products such as excipients for treating these diseases. Growth in the pharmaceutical industry and increasing demand for generic drugs to cater to the increasing demand for pharmaceutical products leads to increasing interest among pharmaceutical companies in investing in drug discovery using pharmaceutical excipients. Increased research and development activities by market players to develop new efficient pharmaceutical excipients, favorable regulatory frameworks, and frequent product launches by the market players play a pivotal role in enhancing the global pharmaceutical excipients market. Moreover, consistent collaboration activities such as mergers and acquisitions, partnerships, and distribution agreements between the organizations further propel the global pharmaceutical excipients market. For instance, in November 2023, IFF's and BASF's pharma solutions divisions announced a collaboration to bring IFF's leading pharmaceutical excipients brands on BASF's "ZoomLab", a virtual pharma assistant platform. This platform enables the researchers to predict and analyze the suitable excipients required for developing new pharmaceutical formulations and assists in overcoming formulation challenges.
Increase in Prevalence of Chronic Diseases
The demand for pharmaceutical excipients is increasing significantly due to the rising prevalence of chronic diseases. The increasing aging population is responsible for the onset of several chronic health conditions such as cardiovascular diseases, cancer, and diabetes. These chronic diseases are fatal and need cost-effective solutions to treat these diseases. According to WHO 2023 statistics, chronic diseases are the most common diseases affecting people from all over the world and are responsible for 41 million deaths every year worldwide. A sedentary lifestyle, unhealthy diet, obesity, excessive tobacco, and alcohol consumption are the leading risk factors for the rising prevalence of chronic diseases among the population. Pharmaceutical excipients are crucial in optimizing drug delivery formats and developing safe and cost-effective drugs. Moreover, key market players are consistently investing in developing innovative and efficient pharmaceutical excipients to cater to the needs of this growing population suffering from chronic health conditions. This is further accelerating the growth of the global pharmaceutical excipients market.
Increasing Demand for Generic Drugs
With the growing prevalence of chronic and infectious diseases worldwide, there is a huge demand for affordable medicines to cater to the needs of the growing diseased population. Pharmaceutical excipients play a significant role in developing cost-effective and safe generic drugs. As a result, the demand for pharmaceutical excipients is also increasing among the pharmaceutical manufacturers. Several leading pharmaceutical companies are consistently involved in the manufacturing of generic drugs. For instance, Teva Pharmaceutical Industries Ltd., which is a global leader in the pharmaceutical industry states that worldwide, around 200 million people take one of their generic medicines every day and a significant portion of the company's research and development budget is focused on developing generic medicines. This growing interest of the major players in investment activities in generic drugs is anticipated to propel the global pharmaceutical excipients market growth.
Pharmaceutical Companies Hold a Significant Market Share
Based on end-user, the pharmaceutical companies hold a significant share due to frequent product launches by the leading pharmaceutical companies. Furthermore, collaboration ventures such as mergers and acquisitions, and partnership agreements lead to faster growth of the pharmaceutical companies in this market. For instance, in July 2023, Roquette, a strong global player in naturally derived pharmaceutical excipients, announced the acquisition of Qualicaps, a Japan-based pharmaceutical company and the third-largest producer of hard capsules for oral dosage solutions. This strategic acquisition is expected to expand Roquette's global reach and enhance its business of pharmaceutical excipients. These frequent collaboration ventures among pharmaceutical companies bring innovation and advancements in pharmaceutical excipients and drive market growth.
Fillers and Diluents Segment Holds a Significant Market Share
Based on functionality, the fillers and diluents segment holds a significant market share in this market. Pharmaceutical excipient's functionality as a filler plays several important roles during drug formulations, especially in tablet and capsule production. Excipients as a fillers play an essential part in adding bulk to the formulations when the active ingredients are too small. For instance, in October 2023, Roquette, which is a market leader in developing pharmaceutical excipients announced the launch of three new pharmaceutical excipients named "LYCATAB CT-LM" partially pregelatinized starch, "MICROCEL 103 SD" and "MICROCEL 113 SD" microcrystalline cellulose. These excipients are multifunctional, offering functionalities such as binding, filler, and disintegrant that help in the development of drugs.
Asia-Pacific is Expected to be the Fastest Growing Region
Asia-Pacific region is expected to be the fastest-growing region in the global pharmaceutical excipients market. Rapidly increasing population and growing prevalence of chronic and infectious diseases in this region accelerate the demand for pharmaceutical products such as excipients, to improve drug discovery and enhance medical facilities. Asia-Pacific is an emerging market that has huge potential in the pharmaceutical industry, due to which key market players are continuously developing partnership collaborations and establishing operational facilities in this region to expand their business and enhance the overall growth of this market globally. For instance, in February 2022, Azelis, a global leading manufacturer of specialty chemicals, announced the expansion of its pharmaceutical business in India by signing a distribution agreement with Roquette, which is a global leader in providing pharmaceutical excipients. This distribution agreement will strengthen Azelis global footprint, and flourish the pharmaceutical excipients industry in Asia-Pacific.
Future Market Scenario (2024-2031F)
The global pharmaceutical excipients market is expected to grow in the future, due to several factors. Primarily, the increasing prevalence of chronic and infectious diseases is accelerating the demand for pharmaceutical products including excipients in the healthcare sector to provide safe and effective medicines. The growing generic drugs market, along with increased research and development activities by public and private organizations to develop efficient and cost-effective generic drugs by using excipients led to the growth of the global pharmaceutical excipients market. Additionally, frequent product launches, collaboration activities, and new entrants in this market are expected to drive market growth in the forecast period. For instance, in September 2023, IFF's Pharma Solutions announced the launch of leading excipient products such as low nitrite excipient solutions for the pharmaceutical industry. These consistent innovative product launches are expected to accelerate growth in this market.
Key Players Landscape and Outlook
In the pharmaceutical excipients market, several pharmaceutical companies are consistently involved in collaboration activities such as establishing strategic partnerships and undergoing distribution agreements, which play an essential role in propelling the global pharmaceutical excipients market's growth. These partnerships enable companies to gain informative insights on the market trends, access each other's knowledge, resources, markets, and technologies, and invest in research and development activities to bring highly efficient and cost-effective pharmaceutical products such as excipients to the market. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative ventures promote innovation, expedite product development, and contribute to the enduring and robust growth of the global market. For instance, in May 2023, Croda International Plc. announced that it has signed an exclusive license agreement with Amyris to supply biotechnology-derived "squalene" as an excipient to be used for various purposes such as vaccine development, drug delivery systems, or nucleic acid delivery systems. Amyris is a worldwide leading synthetic biology company, which will expedite the commercialization of squalene products to the global market, which will further assist in elevating the global pharmaceutical excipients market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.